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ELECTROCORTICAL THERAPY FOR MOTION
SICKNESS
Given a sufficiently provocative stimulus, almost
everyone can be made motion sick, with approxi-
mately one-third experiencing significant symptoms
on long bus trips, on ships, or in light aircraft.1–4
Current countermeasures are either behavioral or
pharmacologic. Behavioral measures include habitua-
tion/desensitization treatment protocols5 as well as
positioning the head in alignment with the direction
of the gravito-inertial force and maintaining a stable
horizontal reference frame.5 Pharmacologic measures
include antimuscarinics, H1 antihistamines, and
sympathomimetics, which all detrimentally impact
upon cognitive function, rendering them inappropri-
ate for occupational use.5 All current therapies are
only partially effective.
Since a functioning vestibular system is critical to
the development of motion sickness,1 we proposed
that suppressing vestibular activity could increase
tolerance to nauseogenic motion stimuli. We previ-
ously showed that application of transcranial direct
current stimulation (tDCS), specifically unipolar
cathodal stimulation over the left parietal cortex,
results in suppression of the vestibular system.6
Herein, we assessed whether such suppression of ves-
tibular activity using tDCS in normal controls may
alleviate motion sickness.
Classification of evidence. This study provides
Class II evidence that in normal volunteers undergo-
ing off-axis rotation, left parietal cortex cathodal
stimulation increases the time to the development
of moderate nausea.
Methods. We implemented a well-established model
of inducing motion sickness termed off-vertical axis
rotation (OVAR). Subjects were seated in a motorized
chair (NKI; Pittsburgh, PA) with the torso restrained
by a 5-point seatbelt with the head, legs, and feet
additionally secured with cushioned clamps. The chair
was rotated rightwards in the dark, accelerating and
tilting gradually over 30 seconds to reach a constant
rotational velocity of 72 deg/s, frequency of 0.2 Hz,
at a tilt of 18 degrees.7 Twenty right-handed subjects
(10 M; 10 F not within 3 days of menstruation) were
randomly allocated into 2 age- and sex-matched groups
(groups 1 and 2). It was ensured that individuals in
both groups were matched for susceptibility to motion
sickness as determined by adult-based motion sickness
questionnaire scores (MSB scores; see the figure, B for
each individual’s susceptibility score).8
The experimental design was specifically chosen
to test whether tDCS is potentially effective as a pro-
phylactic or abortive treatment. Both groups under-
went an initial OVAR session during sham tDCS
stimulation only. The time taken to self-report (1)
onset of symptoms (i.e., stomach awareness); (2)
the primary outcome measure, onset of moderate
nausea (i.e., total OVAR duration, with no upper
time limit); and (3) subsequent self-recovery were re-
corded. Subjects were given a 1-hour rest period in a
separate room, after which all reported full recovery.
Critically, despite recovery, at this time point previ-
ous research has shown that subjects have higher
motion sickness susceptibility,9 thus allowing us to
test the efficacy of tDCS during enhanced suscepti-
bility. After recovery, unipolar tDCS was applied
(1.5 mA with a ramp-up and fade-out time of 10
seconds; electrode placement area 25 cm2; for elec-
trode placement on the scalp, we parted the hair and
electrodes were held in place with an EEG cap6) with
2 possible different polarities in a double-blind
design.6 For group 1 (cathodal) and group 2 (anodal),
stimulation was applied initially for 15 minutes
immediately prior to the second OVAR session over left
parietal cortex and stimulation continued for either a
further 15 minutes during the rotation or until subjects
reported moderate nausea (i.e., whichever came first).
No subjects dropped out or complained of any symp-
toms associated with either tDCS stimulation or tDCS-
mediated vestibular suppression.
Results. The figure summarizes the results of the
experiment. Repeated-measures analysis of variance
for cathodal tDCS stimulation with within-subjects
factors measurement (OVAR duration, first onset of
symptoms, and time to recovery) and condition
(before tDCS, after tDCS) showed a significant
measurement 3 condition interaction (F 5 9.48,
df 5 2, p 5 0.033; figure, A). Post hoc paired t
tests (2-tailed) with Bonferroni corrections showed
that following cathodal stimulation, OVAR duration
(i.e., time taken for the onset of moderate nausea)
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was significantly increased (t 5 2.68, p , 0.05;
figure, A). In contrast, for anodal stimulation, the
measurement 3 condition interaction was not
significant. That is, following left cathodal
stimulation, it took subjects in the second OVAR
session 207 seconds (range 32–382 seconds) longer
to develop moderate nausea, whereas following left
anodal stimulation subjects developed moderate
nausea on average 57 seconds sooner (range 22 to
2153 seconds). Notably, those subjects less
susceptible to motion sickness (i.e., lower MSB
scores) derived the largest benefit following left
cathodal tDCS stimulation (r 5 0.86, p , 0.001;
figure, B). Further, the time taken to recover
following cathodal stimulation was significantly
reduced (t 5 6.0, p , 0.001; figure, A).
Discussion. Following cathodal tDCS over the left
hemisphere, we observed both an increased duration
in the time taken to develop moderate nausea during
OVAR and a more rapid recovery from symptoms. As
no significant effects were observed during anodal
stimulation, this excludes the role of both adaptation
and nonspecific effects due to tDCS.10 We provide a
novel treatment for motion sickness that is, so far,
apparently free of side effects.
*Q. Arshad and N. Cerchiai contributed equally to this work.
From Imperial College (Q.A., N.C., U.G., Y.N., R.E.R., M.A.G.,
A.M.B.), Charing Cross Hospital, London, UK; Otorinolaringoia-
tria 1 Universitaria (N.C., A.P.C.), Pisa, Italy; and the University
of Westminster (J.F.G.), London, UK.
Author contributions: Q. Arshad: conceptualized study, acquired
data, and wrote the manuscript. N. Cerchiai: conceptualized study
and acquired data. U. Goga: acquired data and revised
Figure Effects of electrocortical stimulation on motion sickness susceptibility
(A) (Left upper panel) Following left cathodal transcranial direct current stimulation (tDCS) stimulation, the susceptibility to
motion sickness was reduced, as reflected by the significant increase in off-vertical axis rotation (OVAR) duration required
to induce moderate nausea. Also, we observe a significant reduction in the time taken for symptom recovery. In contrast,
following left anodal stimulation, we did not observe any significant effects (right upper panel). (B) Adult motion sickness
susceptibility scores (MSB) showed significant correlation with the change in OVAR duration (post-pre tDCS) for the left
cathodal stimulation only (left lower panel), indicating that less susceptible subjects derived the largest benefit from tDCS.
Error bars represent standard errors. *p , 0.05; **p , 0.01.
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TPP1 DEFICIENCY: RARE CAUSE OF ISOLATED
CHILDHOOD-ONSET PROGRESSIVE ATAXIA
Neuronal ceroid lipofuscinoses (NCLs) are neurode-
generative disorders characterized by lysosomal ceroid
deposition. Historically, NCLs were classified by
onset age and electron microscopy abnormalities as
infantile, late infantile, juvenile, and adult.1,2 Molec-
ular techniques have broadened diagnostic subgroups
with identification of at least 13 NCL genes (http://
www.ucl.ac.uk/ncl/mutation), though categorization
remains difficult due to wide-ranging genetic, allelic,
and phenotypic heterogeneity.1,2
CLN2 disease (late infantile NCL) is an autosomal
recessive disorder associated with deficiency of
tripeptidyl-peptidase-1 (TPP1).1–3 Neurodevelop-
mental regression typically begins between 2 and 4
years of age with onset of seizures, cognitive decline,
ataxia, visual loss, spasticity, and death usually in the
2nd decade.1–3 Tissue electron microscopic studies
typically reveal curvilinear profiles.1,2 A recent report
of 6 adult members in 2 families, with symptom onset
in childhood, broadened the phenotype of TPP1 par-
tial deficiency to include spinocerebellar ataxia
(SCAR7).4,5 All patients were compound heterozy-
gotes (c.509-1G.C/c.1397T.G).4,5 We report a
child with progressive ataxia and compound hetero-
zygous TPP1 mutations (common splice, c.509-
1G.C and c.1029G.C, p. Glu343Asp) associated
with TPP1 enzyme deficiency. This case highlights
the power of next-generation sequencing (NGS) in
diagnosing rare and atypical disease. Increased
awareness of TPP1-deficiency ataxia phenotype is
crucial to identify patients with atypical CLN2 dis-
ease. These patients may benefit from TPP1 enzyme
replacement therapy currently in trials for classic late-
infantile CLN2 disease.
Case report. The patient is a 10-year-old African
American/Caucasian girl with prenatal gastroschisis.
Delivery was by cesarean section at 35 weeks. Devel-
opment was normal except for stuttering (age 3). Fine
motor difficulties began at age 4. Abnormalities of
gait, balance, coordination, and difficulties with aca-
demic performance were noted at age 6. Neurocogni-
tive assessment (age 8) identified impaired visual
processing, visual memory, and attention, and expres-
sive/receptive language skills in the below average to
average range. There has been no frank loss of cogni-
tive skills, although symptoms of cerebellar dysfunc-
tion have been progressive. The patient continues
to ambulate and run independently with balance dif-
ficulties, but can no longer ride a bike.
Neurologic examination is notable for scanning
speech. Ophthalmologic examination demonstrates
unilateral Mittendorf dot, intermittent bilateral
horizontal gaze-evoked nystagmus, saccadic
breakdown of ocular pursuit, overshoot of horizon-
tal saccades, and oculomotor apraxia. Movement
abnormalities include bilateral upper extremity
dysmetria, slowed fine finger movements, and trun-
cal titubation. Gait is wide-based and moderately
unsteady. The patient is able to stand on one foot
Marisela E. Dy, MD
Katherine B. Sims, MD
Jennifer Friedman, MD
Supplemental data
at Neurology.org
Neurology 85 October 6, 2015 1259
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
